| A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma (NCT01309412) | Janssen Pharmaceutical K.K. | 2011-01-01 |
| A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan (NCT01752075) | Celgene | 2011-01-01 |
| UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NCT01313897) | University of Arkansas | 2011-01-01 |
| A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy (NCT00558675) | Mirror Biologics, Inc. | 2010-12-01 |
| IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus (NCT01234974) | Milton S. Hershey Medical Center | 2010-12-01 |
| Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology (NCT01626547) | Hospira, now a wholly owned subsidiary of Pfizer | 2010-12-01 |
| A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NCT01217957) | Millennium Pharmaceuticals, Inc. | 2010-11-22 |
| A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma (NCT00863174) | Sun Pharma Advanced Research Company Limited | 2010-11-01 |
| First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade (NCT01215344) | Vanderbilt-Ingram Cancer Center | 2010-11-01 |
| Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line (NCT01430546) | Hareth Nahi | 2010-11-01 |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma (NCT01183949) | Astex Pharmaceuticals, Inc. | 2010-11-01 |
| Role of BCL-B in Multiple Myeloma (NCT01270009) | Centre Hospitalier Universitaire de Nice | 2010-11-01 |
| A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma (NCT01248455) | National Cancer Institute (NCI) | 2010-11-01 |
| Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation (NCT01251952) | Barbara Ann Karmanos Cancer Institute | 2010-11-01 |
| Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma (NCT01242930) | Geron Corporation | 2010-11-01 |
| Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients (NCT01270932) | University Health Network, Toronto | 2010-11-01 |
| A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma (NCT01122875) | Genentech, Inc. | 2010-11-01 |
| Imaging in MGUS, SMM and MM (NCT01237054) | National Cancer Institute (NCI) | 2010-10-17 |
| Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro (NCT01472627) | Dana-Farber Cancer Institute | 2010-10-01 |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma (NCT01219010) | Janssen Research & Development, LLC | 2010-10-01 |
| SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) (NCT01402687) | Dana-Farber Cancer Institute | 2010-10-01 |
| Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease (NCT00871702) | Washington University School of Medicine | 2010-10-01 |
| A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma (NCT01302392) | Amgen | 2010-09-01 |
| Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma (NCT01199718) | Cylene Pharmaceuticals | 2010-09-01 |
| Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma (NCT01179490) | SymBio Pharmaceuticals | 2010-09-01 |
| A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies (NCT01232712) | Vaxil Therapeutics Ltd. | 2010-09-01 |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies (NCT01204164) | Tragara Pharmaceuticals, Inc. | 2010-08-01 |
| The Pathophysiology of Bortezomib Induced Peripheral Neuropathy (NCT01171443) | Wolfson Medical Center | 2010-08-01 |
| Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma (NCT01380106) | Boston VA Research Institute, Inc. | 2010-08-01 |
| Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma (NCT01159574) | Weill Medical College of Cornell University | 2010-08-01 |
| Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma (NCT01593410) | Celgene | 2010-08-01 |
| Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research (NCT01382615) | Dartmouth-Hitchcock Medical Center | 2010-08-01 |
| Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study (NCT01054196) | Weill Medical College of Cornell University | 2010-08-01 |
| Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM (NCT01114282) | Stanford University | 2010-08-01 |
| A Study of Special Use Results Surveillance of Revlimid 5mg Capsules (NCT02921802) | Celgene | 2010-07-20 |
| Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma (NCT01177397) | Celgene | 2010-07-20 |
| Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide (NCT01166113) | Fondazione EMN Italy Onlus | 2010-07-01 |
| Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone (NCT01190787) | European Myeloma Network B.V. | 2010-07-01 |
| Investigation of Bone Defects and Microcirculation With Computed Tomography and Magnetic Resonance Imaging (NCT01374412) | German Cancer Research Center | 2010-07-01 |
| MSC and HSC Coinfusion in Mismatched Minitransplants (NCT01045382) | University of Liege | 2010-07-01 |
| A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma (NCT01101594) | Gilead Sciences | 2010-07-01 |
| Modified Bortezomib-based Combination Therapy for Multiple Myeloma (NCT02559154) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2010-07-01 |
| "WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival (NCT01171430) | Assistance Publique - Hôpitaux de Paris | 2010-07-01 |
| Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma (NCT01177683) | Sherif Farag, MB, BS | 2010-07-01 |
| Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (NCT01453088) | Hackensack Meridian Health | 2010-06-24 |
| Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study (NCT01139476) | National Cancer Institute (NCI) | 2010-06-15 |
| Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma (NCT01453101) | Hackensack Meridian Health | 2010-06-09 |
| A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer (NCT01149668) | Pharmacyclics LLC. | 2010-06-01 |
| Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma (NCT01168804) | Austrian Forum Against Cancer | 2010-06-01 |
| Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma (NCT01148108) | Telik | 2010-06-01 |
| Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients (NCT01121120) | Tarix Pharmaceuticals | 2010-06-01 |
| A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma (NCT01160380) | Oncotherapeutics | 2010-06-01 |
| Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma (NCT01249690) | Second Military Medical University | 2010-06-01 |
| Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT (NCT01242267) | Hackensack Meridian Health | 2010-05-11 |
| HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies (NCT01119066) | Memorial Sloan Kettering Cancer Center | 2010-05-03 |
| Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy (NCT01056276) | SCRI Development Innovations, LLC | 2010-05-01 |
| Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) (NCT01186224) | University of Liverpool | 2010-05-01 |
| Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (NCT01554852) | University of Leeds | 2010-05-01 |
| IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients (NCT01009840) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2010-05-01 |
| SCRI Tissue Testing Registry (NCT00965861) | SCRI Development Innovations, LLC | 2010-05-01 |
| Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) (NCT01109004) | National Heart, Lung, and Blood Institute (NHLBI) | 2010-05-01 |
| Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions (NCT01131169) | Memorial Sloan Kettering Cancer Center | 2010-05-01 |
| Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma (NCT01241708) | Hackensack Meridian Health | 2010-04-08 |
| Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse (NCT01087008) | PETHEMA Foundation | 2010-04-01 |
| UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma (NCT01621672) | University of Arkansas | 2010-04-01 |
| Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma (NCT01045681) | Intergroupe Francophone du Myelome | 2010-03-03 |
| Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma (NCT01090089) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-03-01 |
| Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (NCT01459653) | Sandoz | 2010-03-01 |
| Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation (NCT01067287) | Beth Israel Deaconess Medical Center | 2010-03-01 |
| Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer (NCT00963872) | Masonic Cancer Center, University of Minnesota | 2010-03-01 |
| Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma (NCT01057225) | Mayo Clinic | 2010-03-01 |
| Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure (NCT01084837) | PETHEMA Foundation | 2010-03-01 |
| A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma (NCT01063907) | Kyowa Kirin Co., Ltd. | 2010-03-01 |
| Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) (NCT01114048) | Chonnam National University Hospital | 2010-03-01 |
| Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection (NCT01042717) | Shi, Patricia, M.D. | 2010-02-01 |
| Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine (NCT01006070) | University of California, San Francisco | 2010-02-01 |
| Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma (NCT01686386) | Gruppo Italiano Studio Linfomi | 2010-02-01 |
| Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients (NCT01018979) | GPCR Therapeutics, Inc. | 2010-02-01 |
| Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma (NCT01045460) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2010-01-15 |
| A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma (NCT01038388) | Emory University | 2010-01-15 |
| Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma (NCT01054144) | H. Lee Moffitt Cancer Center and Research Institute | 2010-01-14 |
| Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy (NCT01023880) | Cephalon | 2010-01-01 |
| Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 (NCT02858999) | Centre Hospitalier Universitaire, Amiens | 2010-01-01 |
| Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma (NCT01062230) | University of Arkansas | 2010-01-01 |
| PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation (NCT00925782) | Acrotech Biopharma Inc. | 2010-01-01 |
| Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization (NCT01037517) | CancerCare Manitoba | 2010-01-01 |
| Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01716364) | Peter MacCallum Cancer Centre, Australia | 2010-01-01 |
| Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma (NCT00965224) | Zwi Berneman | 2010-01-01 |
| Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma (NCT01050790) | Virginia Commonwealth University | 2010-01-01 |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders (NCT01177527) | Dana-Farber Cancer Institute | 2009-12-30 |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (NCT01023308) | Novartis Pharmaceuticals | 2009-12-21 |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant (NCT00998049) | Mayo Clinic | 2009-12-01 |
| Bortezomib Consolidation Trial (NCT01517724) | University College, London | 2009-12-01 |
| IMGN901 in Combination With Lenalidomide and Dexamethasone (NCT00991562) | ImmunoGen, Inc. | 2009-12-01 |
| Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients (NCT01002248) | AEterna Zentaris | 2009-12-01 |
| A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma (NCT01025206) | BioInvent International AB | 2009-12-01 |
| Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma (NCT01019174) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2009-11-01 |
| Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib (NCT01060202) | Janssen Korea, Ltd., Korea | 2009-11-01 |
| UARK 2009-32 Compassionate Use Study of Carfilzomib (NCT00999414) | University of Arkansas | 2009-11-01 |
| Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy (NCT01016548) | University Health Network, Toronto | 2009-11-01 |